4th Quarter - Report

EXPRESS SCRIPTS, INC. for EXPRESS SCRIPTS, INC.

Firm
Client
Income
—
Expenses
$630,728
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).

LobbyistCovered position, as disclosed
ROBERT W LIVELY —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Government Accountability Office (GAO); Internal Revenue Service (IRS); Health Resources & Services Administration (HRSA); Labor, Dept of (DOL); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); White House Office; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Congressional Budget Office (CBO); Federal Trade Commission (FTC); Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: S. 2289 (112th), S. 2236 (112th), S. 2516 (112th), H.R. 3988 (112th), H.R. 4087 (112th), S. 3187 (112th), H.R. 5334 (112th)

Taxation/Internal Revenue Code TAX

Regulatory implementation of various tax provisions in the health reform legislation

LobbyistCovered position, as disclosed
ROBERT W LIVELY —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Labor, Dept of (DOL); White House Office; Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Government Accountability Office (GAO); Internal Revenue Service (IRS); Congressional Budget Office (CBO); Federal Trade Commission (FTC); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Labor Issues/Antitrust/Workplace LBR

Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).

LobbyistCovered position, as disclosed
ROBERT W LIVELY —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS); Internal Revenue Service (IRS); White House Office; Federal Trade Commission (FTC); Government Accountability Office (GAO); Labor, Dept of (DOL); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Executive Office of the President (EOP); SENATE; Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA)

Bills named: H.R. 1409 (112th), H.R. 1839 (112th), H.R. 1946 (112th)

Postal POS

Postal Reform proposals and their impact on 6 day mail delivery: S 1789 and HR 2309

LobbyistCovered position, as disclosed
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Labor, Dept of (DOL); White House Office; Executive Office of the President (EOP); Food & Drug Administration (FDA); Government Accountability Office (GAO); Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Congressional Budget Office (CBO); Federal Trade Commission (FTC); Internal Revenue Service (IRS)

Bills named: H.R. 2309 (112th)

Defense DEF

Pharmacy issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act of 2012--specifically promotion of House TMOP demonstration program

LobbyistCovered position, as disclosed
NANCY GILBRIDE —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Labor, Dept of (DOL); SENATE; Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); Government Accountability Office (GAO); Executive Office of the President (EOP); Federal Trade Commission (FTC); Internal Revenue Service (IRS); Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); White House Office; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Medicare/Medicaid MMM

Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)

LobbyistCovered position, as disclosed
ROBERT W LIVELY —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Government Accountability Office (GAO); Health Resources & Services Administration (HRSA); Congressional Budget Office (CBO); SENATE; Federal Trade Commission (FTC); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); White House Office; Labor, Dept of (DOL); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Internal Revenue Service (IRS); Executive Office of the President (EOP)

Bills named: H.R. 4215 (112th), H.R. 2190 (112th), H.R. 905 (112th), H.R. 2248 (112th), H.R. 891 (112th)

Pharmacy PHA

Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.

LobbyistCovered position, as disclosed
ROBERT W LIVELY —
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Executive Office of the President (EOP); Government Accountability Office (GAO); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Internal Revenue Service (IRS); Health & Human Services, Dept of (HHS); Labor, Dept of (DOL); SENATE; Federal Trade Commission (FTC); White House Office; HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Congressional Budget Office (CBO)

Bills named: H.R. 3988 (112th), S. 3187 (112th), H.R. 979 (112th), H.R. 5334 (112th), H.R. 1971 (112th), S. 2516 (112th), S. 2236 (112th), S. 27 (112th), S. 2289 (112th), H.R. 4087 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.